Search / Trial NCT00000656

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Didanosine Drug Therapy, Combination Zidovudine

Description

Because of the failure with long-term (more than 1 year) use of, frequency of toxicity from, and drug resistance to AZT, drug combinations need to be developed to enable lower, less toxic doses of AZT to be used and to slow or prevent the development of resistance, while providing at least the same effectiveness. Enrollment during the first 8 weeks of the study is restricted to hemophiliacs and sexual partners of hemophiliacs with asymptomatic HIV disease. After the initial 8 weeks this restriction is lifted. Patients are randomized to one of four treatment arms with dosing of AZT plus ddI...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Aerosolized pentamidine.
  • Acute and intermittent therapy with mycostatin and mycelex.
  • Isoniazid, if no alternative therapy is available.
  • Allowed for up to 2 weeks:
  • Acyclovir for Herpes infection (withhold didanosine during therapy).
  • Acute therapy with fluconazole or ketoconazole.
  • Allowed but preferably not on a continuous basis for > 72 hours:
  • Acetaminophen.
  • Ibuprofen.
  • Nonsteroidal antiinflammatory agents.
  • Patients must be:
  • HIV antibody positive.
  • Asymptomatic or have persistent generalized lymphadenopathy.
  • Diagnosed with one of the listed coagulopathies.
  • OR Sexual partner of someone with the above criteria.
  • Allowed:
  • Basal cell carcinoma or in situ carcinoma of the cervix.
  • NOTE:
  • As of January, 1991 full accrual of patients with prior AZT use has been reached - NOW ACCRUING ONLY THOSE WITH NO PRIOR AZT USE. Hemophilia restriction has been lifted.
  • Prior Medication:
  • Allowed:
  • Zidovudine (AZT) for a total of = or < 13 months.
  • NOTE:
  • As of January, 1991 accrual of these patients was reached, NOW ONLY PATIENTS WITH NO PRIOR AZT.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • Unexplained temperature > 38 degrees C for more than 5 consecutive days or on more than 10 days in any 30-day period in the 2 years prior to study entry.
  • Unexplained diarrhea defined as at least 3 liquid stools/day persisting more than 7 days within 2 years prior to study entry.
  • Unintentional weight loss of > 10 pounds or > 10 percent of usual body weight within 2 years prior to study entry.
  • Oral hairy leukoplakia at any time prior to study entry.
  • Recurrent oral candidiasis unrelated to the use of antibiotics within 2 years prior to entry or unrelated to the use of antibiotics within the past 3 months.
  • Herpes zoster within 2 years prior to study entry.
  • Seizures within the past 6 months or currently requiring anticonvulsants for control.
  • Current heart disease.
  • Current psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy.
  • Gout.
  • Concurrent Medication:
  • Excluded:
  • Rifampin.
  • Chemoprophylaxis for Pneumocystis carinii pneumonia other than aerosolized pentamidine.
  • Intravenous pentamidine.
  • Other antiretroviral agents, experimental medication, biological response modifiers, systemic corticosteroids, cimetidine, and ranitidine.
  • Barbiturates.
  • Oral acidifying agents.
  • Patients with a history of any of the following are excluded:
  • AIDS-defining opportunistic infection, advanced AIDS-related complex, or malignancy.
  • Acute or chronic pancreatitis.
  • Grade 2 or higher neuropathy based on the Neuropathy Targeted Symptom Questionnaire.
  • Seizures.
  • Zidovudine therapy for = or > 13 months.
  • Heart disease.
  • Psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy.
  • Gout.
  • Prior Medication:
  • Excluded within 4 weeks of study entry:
  • Antiretroviral agents, including ribavirin, HPA-23, rifampin, AL721.
  • Excluded within 3 months of study entry:
  • Significant course of immunomodulating agents, such as steroids (> 1 week), isoprinosine, thymic factors, or any other experimental drugs.
  • Excluded within 30 days prior to study entry:
  • Neurotoxic drugs.
  • Excluded:
  • Didanosine (ddI).
  • Dideoxycytidine (ddC).
  • Zidovudine (AZT) if received for > 13 months.
  • Prior Treatment:
  • Excluded within 3 months of entry:
  • Other experimental therapy.
  • History of recent alcohol abuse.

Attachments

readout_NCT00000656_2024-03-05.pdf

4.5 MB

NCT00000656_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Seattle, Washington, United States

Palo Alto, California, United States

Washington, District Of Columbia, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0